Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  clear cell renal cell carcinoma
Stage/Subtype:  clear cell renal cell carcinoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 32 for your search:
Start Over
Everolimus in Treating Patients with Kidney Cancer Who Have Undergone Surgery
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: S0931, NCI-2011-02028, CDR0000668388, SWOG-S0931, NCT01120249
Pazopanib Hydrochloride in Treating Patients with Metastatic Kidney Cancer Who Have No Evidence of Disease after Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: E2810, NCI-2012-00723, CDR0000730383, ECOG-E2810, NCT01575548
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-214, NCI-2014-01993, 2014-001750-42, NCT02231749
A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: WO29637, NCI-2015-01390, 2014-004684-20, NCT02420821
Entinostat in Combination with Aldesleukin in Treating Patients with Metastatic Kidney Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 145208, NCI-2012-02900, CDR0000662915, NCI 7870, NCT01043159, RPCI #23, 7870, NCT01038778
Hydroxychloroquine and Aldesleukin in Treating Patients With Metastatic Kidney Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IIT11PLK01, NCI-2012-00427, 11-080, 1302010628, NCT01550367
Panobinostat and Everolimus in Treating Patients with Metastatic or Unresectable Renal Cell Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 146308, NCI-2009-01599, NCT01037257, NCT01582009
Pazopanib Hydrochloride and Bevacizumab in Treating Patients with Previously Untreated Metastatic Kidney Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 191711, NCI-2012-01247, 13-069, NCT01684397
Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RX-0201-P2-A-09, NCI-2014-02443, NCT02089334
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-04, NCI-2015-00740, NCT02386111
Everolimus Before and After Surgery in Treating Patients With Stage IV Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: H-23409, NCI-2012-00764, 06-08-20-01, NCT00831480
Sunitinib Malate with or without Gemcitabine Hydrochloride in Treating Patients with Advanced Kidney Cancer That Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: E1808, NCI-2011-02055, CDR0000681614, ECOG-E1808, NCT01164228
Pazopanib Hydrochloride or Temsirolimus in Treating Patients With Metastatic or Locally Advanced Kidney Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0358, NCI-2011-01277, NCT01392183
Pazopanib Hydrochloride before Surgery in Treating Patients with Locally Advanced Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: LCCC 1028, NCI-2013-00943, 11-0457, NCT01361113
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A041-04, NCI-2013-00667, ACE-041, NCT01727336
Sunitinib Malate on an Alternative Schedule in Treating in Patients with Metastatic Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0944, NCI-2014-01908, NCI-2014-01171, NCT02060370
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CDX1127-01, NCI-2012-00801, NCT01460134
Donor Hematopoietic Stem Cell Transplant in Treating Young Patients with Relapsed or Refractory Solid Tumors or Lymphomas
Phase: Phase I
Type: Treatment
Age: 2 to 21
Trial IDs: RADIANT, NCI-2012-00588, NCT01625351
A Study of MPDL3280A Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GP28328, NCI-2013-00509, 2012-001422-10, NCT01633970
Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-000577, NCI-2013-00646, NCT01826877
Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients with Metastatic Kidney Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RENAL0027, NCI-2013-01688, NCT01943188
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A4061068, NCI-2014-00350, 2015-001724-31, NCT01999972
Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 200249, NCI-2014-02648, NCT02014636
Immunotherapy Study for Metastatic Renal Cell Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NLG0106, NCI-2015-00313, NCT02035358
Start Over